The Supreme Court has asked the Justice Department to weigh in on a so-called skinny label case over whether brand drug makers can patent new uses of their drugs in a bid to keep generic drugs from entering the market. There are few details about the request on the high court’s case docket, Teva Pharmaceuticals USA Inc. v. GlaxoSmithKline LLC (No. 22-37). The docket simply says the solicitor general is invited to file a brief “expressing the views of...

A coalition of patient and provider groups urges CMS to bar insurers from exempting drug manufacturer coupons from cost-sharing limits in the 2024 exchange rule, and stakeholders also urge HHS to consider the so-called “co-pay accumulators” discriminatory in its final rule on Section 1557 of the Affordable Care Act. Although Medicare bans the use of drug manufacturers’ co-pay coupons, they are allowed in the private market, including Affordable Care Act plans. Insurers say the coupons encourage high drug prices and...